Loading…
← CockpitCompetitor Analysis › CBIO Crescent Biopharma, Inc.Open in the cockpit ↗

Crescent Biopharma, Inc.CBIOCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum weak 23
Mkt cap
$482M
US dollars, full cap
Free float
83%
of shares outstanding
$/day
$3.21M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 12.0%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · USD$12.40
1D-4.9%
1W-16.0%
1M-5.1%
3M-23.6%
6M-34.4%
YTD+4.5%
1Y-5.1%
ATR %9.1%
Beta1.25
52w lowhigh54.8% off high

What Crescent Biopharma does

Employees: 44

Crescent Biopharma at a glance

Size Crescent Biopharma (CBIO) is a United States Health Care company (Biotechnology) with a market value of $482M, the 2694th largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.40 on 18 Nov 2026.

Performance Over six months the shares fell 34.4%, against -5.6% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 18 in its peer set.

Growth The operating margin is -1,216.6% (peer median -11.6%).

Valuation It trades at 13.3× enterprise value to sales against a peer median of 7.5× (5th most expensive of 14).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 90CBIO 61
Six months, rebased to 100: Crescent Biopharma against the median of its 20 peers (local-currency closes).

Crescent Biopharma financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$15.0M$10.8M$0$10,000$75,000
Revenue growth——-100%-87%—
Gross profit$14.7M$10.8M$0-$143,301-$957,156
EBITDA-$182M-$153M-$17.2M-$39.1M-$46.4M
Net income-$178M-$154M-$17.9M-$36.9M-$46.7M
Free cash flow-$82.4M-$72.5M-$6.27M-$34.9M-$46.5M
Capital expenditure$80.4M$72.9M$0$21,394$84,191
Total debt$2.46M$1.64M$41.5M$808,402$918,555

Quarterly statements and history in the cockpit →

Crescent Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%4147MNPRNGNE6586603255FENC688247KMDA300858DMACVLASTTK041960115180CBIO6-month return →1-month return →
Up and to the right = strong over both horizons. Crescent Biopharma is the large dot.

Crescent Biopharma competitors and peer comparison

How Crescent Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Crescent Biopharma against its 20 peers (data as of 18 Nov 2026)
MeasureCBIOPeer medianRank in peer set
1-month return-5.1%-11.1%8th highest of 21
6-month return-34.4%-5.6%2nd lowest of 18
Distance from 52-week high-54.8%-44.6%4th lowest of 21
Operating margin-1,216.6%-11.6%3rd lowest of 15
EV / Sales13.3×7.5×5th most expensive of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Crescent Biopharma CBIOUnited States$482M-34%n/a-1,217%13.3×n/an/a
TaiMed Biologics 4147.TWOTaiwan$480M+19%+7%-31%22.7×n/an/a
Monopar Therapeutics MNPRUnited States$479M+9%n/an/an/an/an/a
Neurogene NGNEUnited States$479M-14%-100%n/an/an/an/a
CHO Pharma 6586.TWOTaiwan$488M+24%-47%-17,694%8,281.1×n/an/a
Liaoning Dingjide Petrochemical 603255.SSChina$490M-24%+70%5%5.2×n/an/a
Fennec Pharmaceuticals FENCUnited States$471M+37%+71%5%6.4×58.8%+204.7%
Sinotherapeutics 688247.SSChina$494M-19%-17%0%6.2×29.4%+7.0%
TenNor Therapeutics Suzhou 6872.HKHong Kong$470Mn/an/an/an/an/an/a
Kamada KMDAUnited States$465M+3%+5%15%2.0×5.0%+6.5%
Beijing Scitop Bio-Tech 300858.SZChina$501M-28%+4%8%7.5×n/an/a
DiaMedica Therapeutics DMACUnited States$463M+50%n/an/an/an/an/a
HanchorBio 7827.TWTaiwan$462Mn/an/a-4,673%509.6×n/an/a
Valneva VLA.PAFrance$508M-6%-27%-87%3.9×n/an/a
LongBio Pharma (Suzhou) 1779.HKHong Kong$510Mn/an/an/an/an/an/a
Shattuck Labs STTKUnited States$455M-28%-100%n/an/an/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Beijing Bohui Innovation Biotechnology 300318.SZChina$518M-20%-1%-13%6.2×n/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a

Questions

Which companies are Crescent Biopharma's closest peers?
The cockpit's peer set: TaiMed Biologics (4147.TWO), Monopar Therapeutics (MNPR), Neurogene (NGNE), CHO Pharma (6586.TWO), Liaoning Dingjide Petrochemical (603255.SS), Fennec Pharmaceuticals (FENC), Sinotherapeutics (688247.SS), TenNor Therapeutics Suzhou (6872.HK).
Is Crescent Biopharma expensive compared with its peers?
On ev / sales it trades at 13.3× against a peer median of 7.5×, 5th most expensive of 14 in its peer set.
How has Crescent Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned -34.4% against -5.6% for the median peer; over one year -5.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.